GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PLx Pharma Winddown Corp (OTCPK:PLXPQ) » Definitions » 5-Year Yield-on-Cost %

PLx Pharma Winddown (PLx Pharma Winddown) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is PLx Pharma Winddown 5-Year Yield-on-Cost %?

PLx Pharma Winddown's yield on cost for the quarter that ended in Sep. 2022 was 0.00.


The historical rank and industry rank for PLx Pharma Winddown's 5-Year Yield-on-Cost % or its related term are showing as below:



PLXPQ's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.22
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of PLx Pharma Winddown's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, PLx Pharma Winddown's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PLx Pharma Winddown's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PLx Pharma Winddown's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where PLx Pharma Winddown's 5-Year Yield-on-Cost % falls into.



PLx Pharma Winddown 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of PLx Pharma Winddown is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

PLx Pharma Winddown  (OTCPK:PLXPQ) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


PLx Pharma Winddown 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of PLx Pharma Winddown's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


PLx Pharma Winddown (PLx Pharma Winddown) Business Description

Traded in Other Exchanges
N/A
Address
8 The Green, Suite 11895, Dover, DE, USA, 19901
PLx Pharma Winddown Corp Formerly PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform designed to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the GI tract. It believes this platform has the potential to improve the absorption of many drugs currently on the market or in development and to reduce the risk of stomach erosions and ulcers associated with drugs. VAZALORE is a novel formulation of aspirin clinically shown to provide fast, reliable and predictable platelet inhibition for patients with vascular disease and diabetic patients who may be candidates for aspirin therapy.
Executives
Rita M O'connor officer: Chief Financial Officer 4 OAK PARKWAY, SPARTA NJ 07871
Natasha Giordano director, officer: Chief Executive Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael J Valentino director, officer: Executive Chairman 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
John Hadden director 1375 S FORT HARRISON AVE, CLEARWATER FL 33756
Robert D. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Molly G. Hardie 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Level One Partners, Llc 10 percent owner 210 RIDGE MCINTIRE ROAD, SUITE 350, CHARLOTTESVILLE VA 22903
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Gary S. Balkema director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Robert Casale director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Anthony Bartsh director C/O PARK WEST ASSET MANAGEMENT, LLC, 900 LARKSPUR CIRCLE, SUITE 165, LARKSPUR CA 94939
Park West Asset Management Llc 10 percent owner 1 LETTERMAN DRIVE, SUITE C5-900, SAN FRANCISCO CA 94129
Efthymios Deliargyris officer: Chief Medical Officer C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Gary L Mossman officer: Chief Operating Officer 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
David Emerson Jorden officer: Acting Chief Financial Officer 2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381

PLx Pharma Winddown (PLx Pharma Winddown) Headlines

From GuruFocus